Piramal Pharma Limited (PPL) announced on March 31, 2021, that it has entered into an agreement to acquire 100% of Hemmo Pharmaceuticals Pvt Ltd, an Indian manufacturer of synthetic peptide active pharmaceutical ingredients (APIs), for an upfront consideration of INR 775 crores plus earn-outs linked to the achievement of milestones. The deal, which is subject to customary regulatory closing conditions, marks the foray of PPL’s contract development and manufacturing organization (CDMO) subsidiary, Piramal Pharma Solutions (PPS), into the development and manufacturing of peptide APIs. Peptide API manufacturing refers to the production of the active ingredient in peptide-based drugs, a segment that has seen increased use in oncology, diabetes, and obesity therapies over the past decade, according to PPL’s CEO of Pharma Solutions, Peter DeYoung.
What Happened: A Strategic Acquisition in Peptide APIs
The acquisition agreement, announced in Mumbai, gives PPL full ownership of Hemmo, a company founded in 1979 by Late J. Hemrajani and described by PPL as one of the few pure-play synthetic peptide API manufacturers in the global marketplace. Hemmo’s portfolio covers more than 30 APIs, including generic peptides, peptide new chemical entities (NCEs), and peptides in clinical development. The company operates a GMP manufacturing facility in Turbhe that has been inspected and deemed compliant by the USFDA, EDQM, WHO, and other international regulatory agencies, as well as an R&D facility in Thane focused on process development. Hemmo has expertise in both solution-phase and solid-phase peptide synthesis and supplies peptide products and custom peptide synthesis to pharmaceutical and research companies in domestic and global markets.
PPL states that the acquisition is expected to add more than 250 employees to PPS, including several PhD scientists and a quality team of more than 60. The deal is PPL’s third pharmaceutical acquisition in the current fiscal year, according to Chairperson Nandini Piramal, and is part of the company’s profitable growth strategy. Financial details beyond the upfront consideration and the earn-out structure were not disclosed. The closing of the transaction is not stated as completed and remains subject to regulatory approvals.
Key Numbers Behind the Hemmo Acquisition
| Item | Detail |
|---|---|
| Upfront consideration | INR 775 crores |
| Earn-outs | Linked to achievement of milestones (amount not disclosed) |
| Stake acquired | 100% |
| Hemmo’s API portfolio | 30+ APIs (generic peptides, peptide NCEs, clinical-stage peptides) |
| Hemmo’s operating history | Founded 1979; more than 38 years in business |
| Employees added to PPS (expected) | More than 250, including several PhD scientists and a quality team of over 60 |
| Regulatory certifications | Turbhe facility inspected by USFDA, EDQM, WHO and other agencies |
Why It Matters for Peptide Therapy and Research Peptides
The acquisition signals growing interest in the peptide API manufacturing segment, which supplies the active ingredients for peptide-based medicines, including GLP-1 receptor agonists used in diabetes and obesity treatment, as well as peptides used in oncology and rare diseases. For the peptide therapy industry, which encompasses clinics, telehealth platforms, and compounding pharmacies that rely on a steady supply of peptide APIs, the entry of a large CDMO like PPS could eventually influence supply dynamics and quality standards. However, the deal does not change the regulatory status of any specific peptide product. Peptide APIs are not finished drugs; they require formulation, container closure, and regulatory approval before they can be marketed as medicines. Research peptides, meanwhile, are for research use only and are not approved for human administration.
Industry observers note that the acquisition may enhance PPS’s ability to offer integrated services, combining drug substance and drug product manufacturing. PPS already operates 14 global facilities and a distribution network in over 100 countries, and in October 2020 received a 20% strategic growth investment from the Carlyle Group. The addition of Hemmo’s peptide API capabilities could position PPS to serve pharmaceutical and research customers seeking peptide-based therapies. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Research and Market Context
Peptide drugs have seen increased use in oncology, diabetes, and obesity over the past decade, according to Peter DeYoung, CEO of Pharma Solutions at PPL. He also noted that the growth in therapies for rare diseases and orphan drugs has increased the need for peptides. These statements are attributed to PPL executives and are not independently verified market data. Nevertheless, they reflect a broader trend: peptide-based therapeutics are a growing area of pharmaceutical research and development. For researchers and clinics, the availability of high-quality peptide APIs is critical. A peptide API is the active pharmaceutical ingredient used in drug manufacturing, while a finished drug product combines the active ingredient with appropriate formulation, container closure, manufacturing controls, labeling, and release requirements. API quality alone does not establish finished-product quality or regulatory approval.
The acquisition also highlights the importance of quality documentation and regulatory compliance in peptide manufacturing. Hemmo’s Turbhe facility has been inspected and deemed compliant by US, EU, and Asian regulatory agencies, which may provide assurance to customers regarding its manufacturing standards. However, certifications indicate inspection compliance, not product-level quality or commercial performance. Buyers of peptide APIs should request batch certificates of analysis (COAs), product specifications, analytical method information, impurity profiles, stability data, and manufacturing-site information, among other documents, depending on the intended market and use.
Industry Impact: What It Means for the Peptide Supply Chain
The acquisition could have implications for the peptide supply chain, particularly for clinics and compounding pharmacies that source peptide APIs. A larger, integrated CDMO with peptide API capabilities may increase competition among suppliers and potentially improve access to high-quality APIs. However, the deal’s impact will depend on post-closing integration, customer qualification, and market demand. It is not yet clear how Hemmo’s capabilities will be integrated into PPS or whether the acquisition will lead to changes in product offerings or pricing. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
For peptide therapy clinics, the news may signal a need to evaluate supplier quality and traceability more rigorously. Clinics that use compounded peptides or research peptides should ensure that their suppliers provide documented analytical data and adhere to applicable regulations. The acquisition does not alter the fact that compounded drugs are not FDA-approved as compounded products, and research chemicals are intended for scientific use and should not be assumed suitable for human treatment. Healthcare professionals should consult official regulatory databases and approved prescribing information for any peptide medicine.
What Comes Next
The acquisition is subject to customary regulatory closing conditions, and the timeline for closing has not been disclosed. Once completed, PPS is expected to integrate Hemmo’s 250-plus employees, including PhD scientists and a quality team of over 60. The market will watch for further details on how PPS plans to leverage Hemmo’s peptide API capabilities, including any investments in capacity expansion or new service offerings. For now, the deal represents a notable move by a major CDMO into peptide API manufacturing, a segment that is increasingly important for the development of peptide-based therapies. As the peptide therapy industry continues to evolve, stakeholders should monitor regulatory developments and supply chain dynamics. For those exploring the peptide supply chain, resources such as peptidescm can provide valuable insights into sourcing and quality considerations.
Frequently Asked Questions
What did Piramal Pharma acquire?
Piramal Pharma Limited agreed to acquire 100% of Hemmo Pharmaceuticals Pvt Ltd, an Indian manufacturer of synthetic peptide APIs, for INR 775 crores upfront plus milestone-linked earn-outs.
Why is this acquisition significant for the peptide industry?
It marks Piramal Pharma Solutions’ entry into peptide API development and manufacturing, adding capabilities that complement its existing CDMO services and potentially increasing competition and capacity in the peptide API market.
Does this acquisition affect the regulatory status of peptide products?
No. The acquisition does not change the regulatory status of any peptide product. Peptide APIs are not finished drugs, and research peptides remain for research use only.
What should clinics and researchers know about peptide API quality?
They should request batch-specific COAs, analytical methods, impurity profiles, and stability data from suppliers, and verify that the API is suitable for its intended use. Certifications alone do not guarantee product quality.
When is the acquisition expected to close?
The closing is subject to customary regulatory conditions, and no timeline has been disclosed.
Comments